TrialReader


A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease

NCT06976216 — Phase 3, Recruiting, 586 participants, Bristol-Myers Squibb

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated With Mild to Moderate Alzheimer's Disease (MINDSET 1)

RegistryNCT06976216, acronym MINDSET 1
StatusRecruiting
PhasePhase 3
Study typeInterventional; randomized, parallel, masking: double, treatment
Enrollment586 (Estimated)
SponsorBristol-Myers Squibb (Industry)
ConditionsAlzheimer's Disease
InterventionsKarXT, KarX-EC, Placebo (Drug, other)
Datesstart 2025-07-14, primary completion 2028-09-11 (estimated), completion 2029-02-23 (estimated), first posted 2025-05-16, last updated 2026-11-17
Locations119 sites in United States, Argentina, Australia, Brazil, Canada, Chile, Croatia, Czechia and 11 more countries

Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Alzheimer's Disease All trials of KarXT All trials of KarX-EC

-Summary

The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease

Expand all sections  ·  Collapse all

+Arms and interventions

ArmTypeInterventionsDescription
KarXT + KarX-ECActive comparatorDrug: KarXT; Drug: KarX-EC
PlaceboPlacebo comparatorOther: Placebo
  • KarXT (Drug), also known as BMS-986510: Specified dose on specified days
  • KarX-EC (Drug), also known as BMS-986519: Specified dose on specified days
  • Placebo (Other): Specified dose on specified days

+Outcome measures

Primary outcomes

  • Change from baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale 11 (ADAS-Cog11) [At week 24]
  • Clinician's Interview-Based Impression Plus Caregiver Input (CIBIC+) [At week 24]

Secondary outcomes

  • Change from baseline in Alzheimer's Disease Cooperative Study-Activities of Daily Living scale (ADCS-ADL) [At week 24]
  • Change from baseline in neuro psychiatric inventory (NPI) total score [At week 24]
  • Number of participants with adverse events (AEs) [At week 24]
  • Number of participants with serious adverse events (SAEs) [At week 24]
  • Number of participants with adverse event of special interest (AESIs) [At week 24]
  • Number of participants with AEs leading to study intervention discontinuation [At week 24]
  • Number of participants with AEs leading to study discontinuation [At week 24]
  • Number of participants with AEs leading to death [At week 24]
  • Number of participants with clinically significant changes in vital signs [At week 24]
  • Number of participants with clinically significant changes in electrocardiogram (ECG) tests [At week 24]
  • Number of participants with clinically significant changes in Columbia-Suicide Severity Rating Scale (C-SSRS) tests [At week 24]
  • Number of participants with clinically significant changes in weight [At week 24]
  • Number of participants with clinically significant changes in safety laboratory tests [At week 24]

+Eligibility

Sex: All, ages: 60 Years to 85 Years

Inclusion Criteria

* Participants must have a confirmed diagnosis of Alzheimer's disease (AD), specifically at the mild (stage 4) or moderate (stage 5) dementia stages, as defined by the National Institute on Aging and Alzheimer's Association (NIA-AA) core clinical criteria. The diagnosis of AD pathology must be confirmed through the 2024 revised NIA-AA Workgroup criteria using a stepwise diagnostic approach.
* Participants must have an Mini-Mental State Examination (MMSE) score ranging from 12 through 22, inclusive, at the time of screening.
* Participants must have a designated caregiver who maintains adequate contact (around 10 hours per week or more) and is willing to attend all study visits. The caregiver must also be responsible for reporting on the participant's condition, overseeing medication compliance, and consenting to their involvement in both their own and the participant's study-related activities.
* Participants on acetyl choline esterase inhibitors (AChEIs) and/or memantine, must have been on a stable dosage for at least 12 weeks prior to screening, and agree to maintain this stable dose for the study duration.

Exclusion Criteria

* Participants must not present with any significant or severe medical conditions that could compromise their safety, the ability to comply with or complete the study, or the integrity of the study results. This includes any grade of hepatic impairment, urinary retention, active biliary disease, moderate-severe renal impairment (eGFR of <50 mL/min), and unstable hypertension or tachycardia.
* Participants must not have any primary psychiatric diagnoses such as major depression, schizoaffective disorder, or bipolar disorder, and those with severe psychiatric symptoms that could complicate the interpretation of treatment effects, impair cognitive assessment, or impact study completion.
* Participants must not have a history of schizophrenia or other chronic psychosis, as well as those who have previously been exposed to KarXT or are currently undergoing treatment with disease-modifying anti-amyloid therapies for AD within the past 6 months prior to screening.
* Participants must not have significant pathological findings on brain magnetic resonance imaging (MRI) at screening that reflect significant pathology other than AD or could affect safety or interfere with study procedures.
* Other protocol-defined Inclusion/Exclusion criteria apply.

+Locations (119)

FacilityCityCountryStatus
Healthy Brain ClinicLong Beach, CaliforniaUnited StatesRecruiting
Anderson Clinical ResearchRedlands, CaliforniaUnited StatesRecruiting
Mountain Neurological Research CenterBasalt, ColoradoUnited StatesRecruiting
Georgetown University Medical CenterWashington D.C., District of ColumbiaUnited StatesRecruiting
JEM Research InstituteAtlantis, FloridaUnited StatesRecruiting
VIN-Julie SchwartzbardAventura, FloridaUnited StatesRecruiting
Merritt Island Medical Research, LLCMerritt Island, FloridaUnited StatesRecruiting
Renstar Medical ResearchOcala, FloridaUnited StatesRecruiting
Alzheimer's Research and Treatment CenterStuart, FloridaUnited StatesRecruiting
Charter Research - Lady LakeThe Villages, FloridaUnited StatesRecruiting
Local Institution - 0016Columbus, GeorgiaUnited StatesWithdrawn
Center for Advanced Research & EducationGainesville, GeorgiaUnited StatesRecruiting
Re:Cognition Health - ChicagoChicago, IllinoisUnited StatesRecruiting
Ascension Alexian BrothersElk Grove Village, IllinoisUnited StatesRecruiting
Boston Center for MemoryNewton, MassachusettsUnited StatesRecruiting
HealthPartners Neuroscience CenterSaint Paul, MinnesotaUnited StatesRecruiting
Advanced Memory Research Institute of New JerseyToms River, New JerseyUnited StatesRecruiting
NYU Langone HealthNew York, New YorkUnited StatesRecruiting
Local Institution - 0259New York, New YorkUnited StatesActive not recruiting
SUNY Upstate Medical UniversitySyracuse, New YorkUnited StatesRecruiting
Local Institution - 0007Matthews, North CarolinaUnited StatesActive not recruiting
Ohio State UniversityColumbus, OhioUnited StatesRecruiting
NDx Clinical Research Inc.Dayton, OhioUnited StatesRecruiting
Summit HeadlandsPortland, OregonUnited StatesRecruiting
Local Institution - 0004Abington, PennsylvaniaUnited StatesWithdrawn
Rhode Island Mood & Memory Research InstituteEast Providence, Rhode IslandUnited StatesRecruiting
Neurology Clinic, P.C.Cordova, TennesseeUnited StatesRecruiting
Gadolin ResearchBeaumont, TexasUnited StatesRecruiting
Fundación para el Estudio y Tratamiento de Enfermedades Mentales (FETEM)Buenos Aires, Buenos Aires F.D.ArgentinaRecruiting
Local Institution - 0271Buenos AiresArgentinaNot yet recruiting
Fundación Lennox - Instituto Modelo de NeurologíaCórdobaArgentinaRecruiting
Sanatorio Morra S.A.CórdobaArgentinaRecruiting
Instituto KremerCórdobaArgentinaRecruiting
Southern NeurologyKogarah, New South WalesAustraliaRecruiting
KARA Institute for Neurological DiseasesMacquarie Park, New South WalesAustraliaRecruiting
NeuroCentrixCarlton, VictoriaAustraliaRecruiting
Neurodegenerative Disorders ResearchPerth, Western AustraliaAustraliaRecruiting
St Vincent's Hospital Sydney LimitedDarlinghurstAustraliaRecruiting
L2IP - Instituto de Pesquisas ClínicasBrasília, Federal DistrictBrazilRecruiting
Instituto de Neurologia de CuritibaCuritiba, ParanáBrazilRecruiting
Local Institution - 0266Aracaju, SergipeBrazilNot yet recruiting
Hospital das Clinicas FMUSPSão PauloBrazilRecruiting
OCT Research ULCKelowna, British ColumbiaCanadaRecruiting
Richmond Clinical TrialsRichmond, British ColumbiaCanadaRecruiting
Centricity Research Halifax MultispecialtyHalifax, Nova ScotiaCanadaRecruiting
Ottawa Memory ClinicOttawa, OntarioCanadaRecruiting
Toronto Memory ProgramToronto, OntarioCanadaRecruiting
MoCA Research and Innovation Inc.Greenfield Park, QuebecCanadaRecruiting
Diex Recherche VictoriavilleVictoriaville, QuebecCanadaRecruiting
ALPHA Recherche CliniqueQuébecCanadaRecruiting
Local Institution - 0094Santiago, Santiago MetropolitanChileNot yet recruiting
Especialidades Médicas LYSSantiago, Santiago MetropolitanChileRecruiting
Local Institution - 0241Santiago, Santiago MetropolitanChileNot yet recruiting
Local Institution - 0230AntofagastaChileNot yet recruiting
Local Institution - 0215Zagreb, City of ZagrebCroatiaNot yet recruiting
Poliklinika NeuronZagreb, City of ZagrebCroatiaRecruiting
Klinika za psihijatriju "Vrapče"ZagrebCroatiaRecruiting
Neuro Health CentrumBrno, Brno-městoCzechiaRecruiting
AGE CentrumOlomouc, Olomouc RegionCzechiaRecruiting
A-ShinePilsen, Plzeň-městoCzechiaRecruiting
Neurologická Ambulance - ForbeliPrague, Praha 6CzechiaRecruiting
NeuropsychiatriePrague, Praha 6CzechiaRecruiting
Institut neuropsychiatricke pece (INEP), PrahaPrague, Praha 8CzechiaRecruiting
Vestra ClinicsRychnov nad KněžnouCzechiaRecruiting
Local Institution - 0295Nice, Alpes-MaritimesFranceNot yet recruiting
Local Institution - 0289Toulouse, Haute-GaronneFranceNot yet recruiting
Local Institution - 0290Rouen, Haute-NormandieFranceNot yet recruiting
Local Institution - 0291Montpellier, Languedoc-RoussillonFranceNot yet recruiting
Local Institution - 0299Reims, MarneFranceNot yet recruiting
Hôpital des Charpennes - Hospices Civils de Lyon (HCL)Villeurbanne, RhôneFranceRecruiting
Local Institution - 0294DijonFranceNot yet recruiting
Local Institution - 0301Mannheim, Baden-WurttembergGermanyNot yet recruiting
Universitätsklinikum Münster - Albert Schweitzer CampusMünster, North Rhine-WestphaliaGermanyRecruiting
Universitätsmedizin Johannes Gutenberg Universität MainzMainz, Rhineland-PalatinateGermanyRecruiting
Charite-Universitaetsmedizin Berlin - Campus Benjamin Franklin (CBF)Berlin, State of BerlinGermanyRecruiting
Local Institution - 0300AachenGermanyNot yet recruiting
Local Institution - 0302BerlinGermanyNot yet recruiting
Local Institution - 0277BremenGermanyWithdrawn
Local Institution - 0275HamburgGermanyWithdrawn
TUM KlinikumMunichGermanyRecruiting
University General Hospital of AlexandroupoliAlexandroupoli, Anatolikí Makedonía Kai ThrákiGreeceRecruiting
Local Institution - 0256Athens, AttikíGreeceWithdrawn
Aiginiteio University HospitalAthens, AttikíGreeceRecruiting
University General Hospital of LarissaLarissa, ThessalíaGreeceRecruiting
Local Institution - 0288Bengaluru, KarnatakaIndiaNot yet recruiting
Local Institution - 0282Hyderabad, TelanganaIndiaNot yet recruiting
Local Institution - 0285Hyderabad, TelanganaIndiaNot yet recruiting
Local Institution - 0287Varanasi, Uttar PradeshIndiaNot yet recruiting
Local Institution - 0286Kolkata, West BengalIndiaNot yet recruiting
Fondazione IRCCS Cà Granda Ospedale Maggiore PoliclinicoMilan, LombardyItalyRecruiting
Ospedale San RaffaeleMilan, LombardyItalyRecruiting
Fondazione IRCCS San Gerardo dei TintoriMonza, LombardyItalyRecruiting
Azienda Ospedaliera Spedali Civili di BresciaBresciaItalyRecruiting
Brain Research Center Den Bosch B.V.'s-Hertogenbosch, North BrabantNetherlandsRecruiting
Local Institution - 0297Amsterdam, North HollandNetherlandsNot yet recruiting
Brain Research Center ZwolleZwolle, OverijsselNetherlandsRecruiting
Centrum Medyczne HCPPoznan, Greater Poland VoivodeshipPolandRecruiting
Osrodek Badan Klinicznych CLINSANTE S.C.Torun, Kuyavian-Pomeranian VoivodeshipPolandRecruiting
MlynowaMed PsychiatricBialystok, Podlaskie VoivodeshipPolandRecruiting
Penta Hospitals Badania Kliniczne - Gdańsk 1Gdansk, Pomeranian VoivodeshipPolandRecruiting

19 more sites not listed.

+Investigators

  • Bristol-Myers Squibb, Study director, Bristol-Myers Squibb

My Notes